Cargando…

Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results

Fourteen patients with metastatic pancreatic adenocarcinoma were treated with the long-acting somatostatin (SST) analogue lanreotide. No objective response was obtained, and the median survival was 4 months (range 1.8–7 months). Pancreatic cancer could not be visualized by means of SST-receptor (R)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raderer, M, Hamilton, G, Kurtaran, A, Valencak, J, Haberl, I, Hoffmann, O, Kornek, G V, Vorbeck, F, Hejna, M H L, Virgolini, I, Scheithauer, W
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1999
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362412/ https://www.ncbi.nlm.nih.gov/pubmed/10027326 http://dx.doi.org/10.1038/sj.bjc.6690084

Ejemplares similares

123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer.
por: Raderer, M., et al.
Publicado: (1998)

Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma
por: Scheithauer, W, et al.
Publicado: (1999)

Importance of extensive staging in patients with mucosa-associated lymphoid tissue (MALT)-type lymphoma
por: Raderer, M, et al.
Publicado: (2000)

Somatostatin-receptor scintigraphy for staging and follow-up of patients with extraintestinal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT)-type
por: Raderer, M, et al.
Publicado: (2001)

Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer.
por: Hejna, M., et al.
Publicado: (1998)

Prescription patterns of long-acting somatostatin analogues
por: Machado-Alba, Jorge Enrique, et al.
Publicado: (2017)

Pulmonary neuroendocrine tumours and somatostatin receptor status: an assessment of unlicensed use of somatostatin analogues in the clinical practice
por: Kiesewetter, B., et al.
Publicado: (2022)

Effective treatment of advanced breast cancer with vinorelbine, 5-fluorouracil and l-leucovorin plus human granulocyte colony-stimulating factor.
por: Kornek, G. V., et al.
Publicado: (1998)

Effective treatment of advanced breast cancer with vinorelbine, mitomycin C plus human granulocyte colony-stimulating factor.
por: Kornek, G. V., et al.
Publicado: (1996)

Tissue polypeptide-specific antigen (TPS) in monitoring palliative treatment response of patients with gastrointestinal tumours.
por: Kornek, G., et al.
Publicado: (1995)

Apoptosis is induced in both drug-sensitive and multidrug-resistant hepatoma cells by somatostatin analogue TT-232
por: Diaconu, C-C, et al.
Publicado: (1999)

Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer
por: O'Byrne, K J, et al.
Publicado: (1999)

Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin
por: Kornek, G V, et al.
Publicado: (2000)

The Effect of Long Acting Somatostatin Analogue SMS 201-995 in Acromegaly
por: Choi, Chul Joon, et al.
Publicado: (1987)

Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study
por: Caplin, Martyn E, et al.
Publicado: (2016)

Long-Acting Somatostatin Analogue Safety Monitoring Protocol for Outpatients With Neuroendocrine Tumors
por: Gabrielsen, Jordan, et al.
Publicado: (2019)

Improved Quality of Life in Patients Treated with Peptide Radionuclides
por: Traub-Weidinger, T, et al.
Publicado: (2011)

Somatostatin analogues for the treatment of hyperinsulinaemic hypoglycaemia
por: Haris, Basma, et al.
Publicado: (2020)

Association of Pathology Markers with Somatostatin Analogue Responsiveness in Acromegaly
por: Kontogeorgos, George, et al.
Publicado: (2022)

Impact of Long-Acting Somatostatin Analogues on Glucose Metabolism in Acromegaly: A Hospital-Based Study
por: Shen, Ming, et al.
Publicado: (2018)

Self-Administration of Long-Acting Somatostatin Analogues in NET Patients—Does It Affect the Clinical Outcome?
por: Sowa-Staszczak, Anna, et al.
Publicado: (2021)

Treatment with long-acting lanreotide autogel in early infancy in patients with severe neonatal hyperinsulinism
por: Corda, Heike, et al.
Publicado: (2017)

Scintigraphic evaluation of functional hepatic mass in patients with advanced breast cancer.
por: Virgolini, I., et al.
Publicado: (1993)

Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma
por: Ulrich-Pur, H, et al.
Publicado: (2003)

The effect of somatostatin analogues on postoperative outcomes following pancreatic surgery: A meta-analysis
por: Han, Xianlin, et al.
Publicado: (2017)

Erratum to “Impact of Long-Acting Somatostatin Analogues on Glucose Metabolism in Acromegaly: A Hospital-Based Study”
por: Shen, Ming, et al.
Publicado: (2019)

Somatostatin Analogues for Receptor Targeted Photodynamic Therapy
por: Kaščáková, Slávka, et al.
Publicado: (2014)

Combined treatment of somatostatin analogues with pegvisomant in acromegaly
por: Franck, S. E., et al.
Publicado: (2015)

Differential Effects of Somatostatin, Octreotide, and Lanreotide on Neuroendocrine Differentiation and Proliferation in Established and Primary NET Cell Lines: Possible Crosstalk with TGF-β Signaling
por: Ungefroren, Hendrik, et al.
Publicado: (2022)

Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly
por: Venegas‐Moreno, Eva, et al.
Publicado: (2017)

Expression of Somatostatin Receptor 2 in Somatotropinoma Correlated with the Short-Term Efficacy of Somatostatin Analogues
por: Liu, Wenjuan, et al.
Publicado: (2017)

Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly
por: Salvatori, Roberto, et al.
Publicado: (2009)

Glucagonoma-associated dilated cardiomyopathy refractory to somatostatin analogue therapy
por: Barabas, Michal, et al.
Publicado: (2019)

Growing vascular endothelial cells express somatostatin subtype 2 receptors
por: Watson, J C, et al.
Publicado: (2001)

Somatostatin Receptor 2 Expression Profiles and Their Correlation with the Efficacy of Somatostatin Analogues in Gastrointestinal Neuroendocrine Tumors
por: Watanabe, Hirofumi, et al.
Publicado: (2022)

Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors
por: Saif, Muhammad Wasif, et al.
Publicado: (2018)

The potential role of somatostatin analogues in breast cancer treatment.
por: Pollak, M.
Publicado: (1997)

Feasibility of Imaging Esophageal Cancer with Labeled Somatostatin Analogue
por: Herlin, Gunnar, et al.
Publicado: (2011)

Glycemic profile in patients with acromegaly treated with somatostatin analogue
por: Valea, A, et al.
Publicado: (2015)

Somatostatin analogues for refractory diarrhoea in familial amyloid polyneuropathy
por: Collins, Michael, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7h0dut0kj8minl0plae0udinj9